Method of lowering serum uric acid levels with (S)-tofisopam
Enantiomerically-pure (S)-tofisopam is administered to lower serum uric acid levels in a mammal.
-
Page/Page column 13
(2016/09/12)
Phosphodiesterase inhibitors
The invention relates especially to novel stereospecific derivatives of 2,3-benzodiazepine type as inhibitors of phosphodiesterases, especially 2 and 4, and uses thereof in the therapeutic field, most particularly for preventing and treating pathologies involving a central and/or peripheral disorder. The compounds of the invention more particularly correspond to the general formulae (I) and (II):
-
Page/Page column 15
(2008/06/13)
USE OF TOFISOPAM AS A PDE10A INHIBITOR
The present invention relates to a novel use of Tofisopam for the preparation of a pharmaceutical composition made for treatment of the positivsymptoms and cognitive deficits in schizophrenic patients.
-
Page/Page column 16-17
(2008/06/13)
Conversion process for 2,3-benzodiazepine enantiomers
Methods for the racemization of an enantiomer of a 2,3-benzodiazepine molecule into the corresponding racemic mixture under either basic or acidic conditions are described. Furthermore, the invention relates to the conversion of an enantiomer of tofisopam or its metabolites to the corresponding opposite enantiomer.
-
Page/Page column 2
(2008/06/13)
Method for isolating (R)-tofisopam
(R)-tofisopam, substantially free of the (S)-enantiomer of tofisopam, is obtained by separating the enantiomers of tofisopam by chromatography employing a chiral separation medium comprising (i) (2S)-2-{(1S)[(3,5-dinitrophenyl)carbonylamino]phenylmethyl}-
-
Page 14
(2008/06/13)
More Articles about upstream products of 82059-51-6